Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples